Thông tin thuốc gốc
Chỉ định và Liều dùng
Pulmonary arterial hypertension
Adult: 2.5 mg or 10 mg tid.

Erectile dysfunction
Adult: 50 mg approx 1 hr before sexual intercourse, may adjust depending on response. Max: 100 mg daily.

Pulmonary arterial hypertension
Adult: 5 mg or 20 mg tid.
Child: 1-17 yr ≤20 kg: 10 mg tid; >20 kg: 20 mg tid.
Nhóm bệnh nhân đặc biệt
Patients on CYP3A4 inhibitors: Initially, not more than 25 mg daily.
Patients on ritonavir-boosted HIV inhibitors: Should not exceed 25 mg 48 hrly.
Patients stable on alpha-blockers: Initially, 25 mg.
Suy thận
Erectile dysfunction:
CrCl (mL/min) Dosage
<30 Initially, 25 mg.

Pulmonary arterial hypertension:
CrCl (mL/min) Dosage
<30 20 mg bid.

Pulmonary arterial hypertension:
CrCl (mL/min) Dosage
<30 10 mg bid.
Suy gan
Erectile dysfunction: Mild or moderate: Initially, 25 mg. Severe: Contraindicated.
Pulmonary arterial hypertension: Mild or moderate: 20 mg bid. Severe: Contraindicated.

Pulmonary arterial hypertension: Mild or moderate: 10 mg bid. Severe: Contraindicated.
Cách dùng
May be taken with or without food.
Hướng dẫn pha thuốc
Oral susp: Add a total of 90 mL of water in 2 portions, 60 mL for the 1st addition and 30 mL for the 2nd addition, to provide a susp containing 10 mg/mL. After each addition, cap and shake the bottle vigorously for at least 30 sec.
Chống chỉ định
Patient w/ severe CV disorders (e.g. unstable angina, cardiac failure), loss of vision in 1 eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), hypotension (BP <90/50 mmHg), recent history of stroke or MI, known hereditary degenerative retinal disorders. Severe hepatic impairment. Concomitant use w/ nitrates of any form and nicorandil.
Thận trọng
Patient w/ anatomical deformation of the penis or haematological disorders that may predispose to priapism. Not indicated for pulmonary HTN secondary to sickle-cell disease. Mild to moderate hepatic and severe renal impairment. Childn (chronic use). Pregnancy and lactation.
Tác dụng không mong muốn
Headache, flushing, dyspepsia, visual disturbances (e.g. blurred vision, photophobia, chromatopsia, cyanopsia, eye irritation, eye pain and redness); dizziness, insomnia, anxiety, vertigo, epistaxis, nasal congestion, pyrexia, GI disturbances (e.g. diarrhoea, vomiting), priapism; skin rashes, erythema, alopecia, limb/back pain, myalgia, facial oedema, fluid retention, paraesthesia, UTI, dyspnoea, cough, rhinitis, sinusitis, bronchitis, cellulitis, sudden decrease or loss of hearing, anaemia, leucopenia, gynaecomastia, urinary frequency or incontinence, haematuria, seizures, cerebrovascular haemorrhage, transient ischaemic attack, palpitations, syncope, HTN, hypotension. Rarely, hypersensitivity reactions, NAION causing permanent loss of vision, retinal haemorrhage.
Potentially Fatal: Serious CV events (e.g. MI, arrhythmias, tachycardia, unstable angina). 
Thông tin tư vấn bệnh nhân
This drug may cause dizziness and altered vision, if affected, do not drive or operate machinery. Seek medical assistance in cases of prolonged erection (>4 hr) or sudden visual or hearing loss.
Chỉ số theo dõi
Monitor BP and pulse when used concurrently w/ hypotensive drugs in the treatment of pulmonary arterial HTN.
Quá liều
Symptoms: Hypotension, syncope, prolonged erection. Management: Supportive treatment. For severe hypotension, may consider placing the patient in the Trendelenburg position, initiating fluid resuscitation, providing judicious use of an IV α-adrenergic agonist (e.g. phenylephrine), providing a combined α- and β-adrenergic agonist (norepinephrine) for BP support, and/or providing intra-aortic balloon.
Tương tác
Symptomatic HTN may occur when used w/ alpha-blockers. Reduced clearance w/ CYP3A4 inhibitors (e.g. cimetidine, delavirdine, erythromycin, itraconazole, ketoconazole). Increased plasma concentrations w/ HIV-protease inhibitors particularly by ritonavir-boosted regimens. Decreased plasma concentrations w/ CYP3A4 inducers (e.g. rifampicin, bosentan).
Potentially Fatal: Potentiation of hypotensive effects of nitrates of any form and nicorandil.
Tương tác với thức ăn
May increase plasma levels w/ grapefruit juice.
Tác dụng
Mechanism of Action: Sildenafil inhibits phosphodiesterase type-5 (PDE-5) which is responsible for cyclic guanosine monophosphate (cGMP) degradation in the corpus cavernosum. Inhibition of PDE-5 increases cGMP which results in pulmonary vascular smooth muscle cells relaxation.
Onset: Approx 60 min.
Duration: 2-4 hr.
Absorption: Rapidly absorbed from the GI tract. Bioavailability: Approx 40%. Time to peak plasma concentration: W/in 30-120 min.
Distribution: Widely distributed into body tissues. Plasma protein binding: Approx 96%.
Metabolism: Hepatically by CYP3A4 (major route) and CYP2C9 isoenzymes.
Excretion: Mainly via faeces (as metabolites); urine (lesser extent). Terminal half-life: Approx 4 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Sildenafil, CID=135398744, (accessed on Jan. 23, 2020)

Bảo quản
Store between 15-30°C.
Phân loại MIMS
Thuốc trị rối loạn cương và rối loạn xuất tinh / Các loại thuốc tim mạch khác
Phân loại ATC
G04BE03 - sildenafil ; Belongs to the class of drugs used in erectile dysfunction.
Tài liệu tham khảo
Anon. Sildenafil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 07/11/2014.

Buckingham R (ed). Sildenafil Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 07/11/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Sildenafil Citrate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 07/11/2014.

Revatio Tablet, Film Coated; Injection, Solution; Powder, for Suspension (Pfizer Laboratories Div Pfizer Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 10/01/2014.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Sildenafil từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Adagrin
  • Azodra
  • Cupid
  • Daygra
  • Desilmax
  • Edafine
  • Ereluv-50
  • Evadam
  • Hindgra
  • Ildenaf
  • Inta-gra
  • Intasfil
  • Kamagra
  • Lovegra
  • Majegra
  • Maxigra
  • Medovigor
  • Shinafil
  • Sife
  • Sildenafil Badinh Pharma
  • Viagra
  • Vigrow
  • Willmon
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in